logo
  

Mitsubishi Motors FY23 Net Profit Down; Sees Weak Profit, Higher Sales In FY24

Japanese automobile major Mitsubishi Motors Corp. (MMTOF.PK) reported Wednesday that its fiscal 2023 net income attributable to owners of the parent dropped 8.3 percent to 154.71 billion Japanese yen from last year's 168.73 billion yen.

Earnings per share declined to 103.96 yen from 113.36 yen a year ago. Operating income, however, edged up 0.2 percent to 190.97 billion yen from last year's 190.50 billion yen.

Net sales for the year increased 13.5 percent to 2.79 trillion yen from 2.46 trillion yen in the same period last year.

Looking ahead for fiscal year 2024, the company expects profit attributable to be 144 billion yen or 96.85 yen per share, down 6.9 percent from last year. Operating income would be 190 billion yen, down 0.5 percent, while net sales are expected to rise 3.2 percent to 2.88 trillion yen.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Microsoft has launched a new category of Windows PCs designed for Artificial Intelligence (AI) that are slated to be the fastest and most intelligent Windows PCs ever built. The Copilot+ PCs come with built-in AI hardware and will support AI features across the operating system. Hospira, Inc., affiliated to dug major Pfizer Inc., is recalling select lots of Buprenorphine Hydrochloride Injection Carpuject Units and Labetalol Hydrochloride Injection Carpuject Units, according to the U.S. Food and Drug Administration. The recall was initiated due to the potential for incomplete crimp seals. The company has received one customer complaint for one leaking unit. While reporting financial results for the first quarter on Wednesday, off-price retailer TJX Companies, Inc. (TJX) provided its earnings and comparable store sales outlook for the second quarter and raised earnings outlook for the full-year 2024. For the second quarter, the company now expects earnings...

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
RELATED NEWS
Follow RTT